Roberto Molinaro1,2, Mikyung Yu3, Grasiele Sausen1, Colette A Bichsel4, Claudia Corbo3,5, Eduardo J Folco1, Gha Young Lee3, Yuan Liu3, Yevgenia Tesmenitsky1, Eugenia Shvartz1, Galina K Sukhova1, Frederik Kloss1, Kevin J Croce1, Omid C Farokhzad3, Jinjun Shi3, Peter Libby1. 1. Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA. 2. Business Development of Research, IRCCS San Raffaele Hospital, Milan, Italy. 3. Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. 4. Department of Surgery, Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. 5. Department of Medicine and Surgery, Nanomedicine Center NANOMIB, University of Milano-Bicocca, Milano, Italy.
Abstract
AIMS: Recent evidence suggests that 'vulnerable plaques', which have received intense attention as underlying mechanism of acute coronary syndromes over the decades, actually rarely rupture and cause clinical events. Superficial plaque erosion has emerged as a growing cause of residual thrombotic complications of atherosclerosis in an era of increased preventive measures including lipid lowering, antihypertensive therapy, and smoking cessation. The mechanisms of plaque erosion remain poorly understood, and we currently lack validated effective diagnostics or therapeutics for superficial erosion. Eroded plaques have a rich extracellular matrix, an intact fibrous cap, sparse lipid, and few mononuclear cells, but do harbour neutrophil extracellular traps (NETs). We recently reported that NETs amplify and propagate the endothelial damage at the site of arterial lesions that recapitulate superficial erosion in mice. We showed that genetic loss of protein arginine deiminase (PAD)-4 function inhibited NETosis and preserved endothelial integrity. The current study used systemic administration of targeted nanoparticles to deliver an agent that limits NETs formation to probe mechanisms of and demonstrate a novel therapeutic approach to plaque erosion that limits endothelial damage. METHODS AND RESULTS: We developed Collagen IV-targeted nanoparticles (Col IV NP) to deliver PAD4 inhibitors selectively to regions of endothelial cell sloughing and collagen IV-rich basement membrane exposure. We assessed the binding capability of the targeting ligand in vitro and evaluated Col IV NP targeting to areas of denuded endothelium in vivo in a mouse preparation that recapitulates features of superficial erosion. Delivery of the PAD4 inhibitor GSK484 reduced NET accumulation at sites of intimal injury and preserved endothelial continuity. CONCLUSIONS: NPs directed to Col IV show selective uptake and delivery of their payload to experimentally eroded regions, illustrating their translational potential. Our results further support the role of PAD4 and NETs in superficial erosion. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Recent evidence suggests that 'vulnerable plaques', which have received intense attention as underlying mechanism of acute coronary syndromes over the decades, actually rarely rupture and cause clinical events. Superficial plaque erosion has emerged as a growing cause of residual thrombotic complications of atherosclerosis in an era of increased preventive measures including lipid lowering, antihypertensive therapy, and smoking cessation. The mechanisms of plaque erosion remain poorly understood, and we currently lack validated effective diagnostics or therapeutics for superficial erosion. Eroded plaques have a rich extracellular matrix, an intact fibrous cap, sparse lipid, and few mononuclear cells, but do harbour neutrophil extracellular traps (NETs). We recently reported that NETs amplify and propagate the endothelial damage at the site of arterial lesions that recapitulate superficial erosion in mice. We showed that genetic loss of protein arginine deiminase (PAD)-4 function inhibited NETosis and preserved endothelial integrity. The current study used systemic administration of targeted nanoparticles to deliver an agent that limits NETs formation to probe mechanisms of and demonstrate a novel therapeutic approach to plaque erosion that limits endothelial damage. METHODS AND RESULTS: We developed Collagen IV-targeted nanoparticles (Col IV NP) to deliver PAD4 inhibitors selectively to regions of endothelial cell sloughing and collagen IV-rich basement membrane exposure. We assessed the binding capability of the targeting ligand in vitro and evaluated Col IV NP targeting to areas of denuded endothelium in vivo in a mouse preparation that recapitulates features of superficial erosion. Delivery of the PAD4 inhibitor GSK484 reduced NET accumulation at sites of intimal injury and preserved endothelial continuity. CONCLUSIONS: NPs directed to Col IV show selective uptake and delivery of their payload to experimentally eroded regions, illustrating their translational potential. Our results further support the role of PAD4 and NETs in superficial erosion. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Juliana M Chan; Liangfang Zhang; Rong Tong; Debuyati Ghosh; Weiwei Gao; Grace Liao; Kai P Yuet; David Gray; June-Wha Rhee; Jianjun Cheng; Gershon Golomb; Peter Libby; Robert Langer; Omid C Farokhzad Journal: Proc Natl Acad Sci U S A Date: 2010-01-19 Impact factor: 11.205
Authors: Grégory Franck; Thomas L Mawson; Eduardo J Folco; Roberto Molinaro; Victoria Ruvkun; Daniel Engelbertsen; Xin Liu; Yevgenia Tesmenitsky; Eugenia Shvartz; Galina K Sukhova; Jean-Baptiste Michel; Antonino Nicoletti; Andrew Lichtman; Denisa Wagner; Kevin J Croce; Peter Libby Journal: Circ Res Date: 2018-03-23 Impact factor: 17.367
Authors: Huw D Lewis; John Liddle; Jim E Coote; Stephen J Atkinson; Michael D Barker; Benjamin D Bax; Kevin L Bicker; Ryan P Bingham; Matthew Campbell; Yu Hua Chen; Chun-Wa Chung; Peter D Craggs; Rob P Davis; Dirk Eberhard; Gerard Joberty; Kenneth E Lind; Kelly Locke; Claire Maller; Kimberly Martinod; Chris Patten; Oxana Polyakova; Cecil E Rise; Martin Rüdiger; Robert J Sheppard; Daniel J Slade; Pamela Thomas; Jim Thorpe; Gang Yao; Gerard Drewes; Denisa D Wagner; Paul R Thompson; Rab K Prinjha; David M Wilson Journal: Nat Chem Biol Date: 2015-01-26 Impact factor: 15.040
Authors: Won Il Choi; Nazila Kamaly; Lorena Riol-Blanco; In-Hyun Lee; Jun Wu; Archana Swami; Cristian Vilos; Basit Yameen; Mikyung Yu; Jinjun Shi; Ira Tabas; Ulrich H von Andrian; Sangyong Jon; Omid C Farokhzad Journal: Nano Lett Date: 2014-10-21 Impact factor: 11.189
Authors: Jaya Krishnan; Néstor de la Visitación; Elizabeth M Hennen; Venkataraman Amarnath; David G Harrison; David M Patrick Journal: Hypertension Date: 2022-06-10 Impact factor: 9.897